Clinical Trials Browser

Completed × Panitumumab × Genitourinary × Clear all

Prostatic Neoplasms

NCT00425035 2013-05-13

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Phase 2 Completed

115 enrolled

Genitourinary

Kidney Neoplasms

NCT00004879 2013-01-08

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Phase 1 Completed

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00425204 2008-09-15

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

Phase 2 Completed

31 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

NCT00061126 2005-06-24

ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

Phase 2 Completed

50 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body